Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parotid Oncocytomas Express the Glycoprotein Non-metastatic Melanoma Protein B (GPNMB): A Potential Link with Birt-Hogg-Dubé Syndrome.

Head and neck pathology·2026
Same author

Splenogonadal Fusion.

Mayo Clinic proceedings·2026
Same author

Imaging Mass Spectrometry-Based Assessment of ER, PR, and HER2 Protein Expression in Breast Cancer.

Proteomics·2026
Same author

Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer.

Cancers·2025
Same author

Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer.

Carcinogenesis·2025
Same author

White Blood Cell Enumeration and Differential by Flow Cytometry: The ICSH WBC Reference Method.

International journal of laboratory hematology·2025

Related Experiment Video

Updated: Jun 17, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Circulating tumor cell analysis: technical and statistical considerations for application to the clinic.

Alison L Allan1, Michael Keeney

  • 1London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada N6A 5W9.

Journal of Oncology
|January 6, 2010
PubMed
Summary

Detecting circulating tumor cells (CTCs) in blood is key for predicting cancer metastasis. This review covers technical and statistical needs for reliable CTC assays in clinical practice.

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Area of Science:

  • Oncology
  • Biotechnology
  • Medical Diagnostics

Background:

  • Solid cancers are a major global health burden, with metastasis being a primary cause of mortality.
  • Circulating tumor cells (CTCs) in blood show promise as biomarkers for metastatic potential and patient prognosis.
  • Current detection methods for CTCs include PCR, flow cytometry, and microchip technology.

Purpose of the Study:

  • To review the technical and statistical considerations for developing and validating robust circulating tumor cell (CTC) assays.
  • To guide the interpretation of CTC analysis for clinical decision-making.

Main Methods:

  • Review of current technologies for CTC enumeration and characterization.
  • Discussion of technical challenges related to the rarity of CTCs.
  • Analysis of statistical requirements for assay validation.

Main Results:

  • Technological advancements enable CTC detection and characterization.
  • The rarity of CTCs necessitates highly sensitive and validated detection methods.
  • Careful consideration of technical and statistical factors is crucial for clinical implementation.

Conclusions:

  • Standardized and validated CTC assays are essential for clinical utility.
  • Accurate interpretation of CTC data can improve patient management and treatment strategies.
  • Further development in CTC detection technology and statistical analysis is needed for widespread clinical adoption.